ReP USP - Resultado da busca

Filtros : "GRU025" "FARMACODINÂMICA" "FCF" Removidos: "ICB-BMF" "Financiado pela Colgate Palmolive" "Financiamento FUSP" Limpar

Filtros

Trabalho de evento-resumo periodico
Pharmacokinetic-pharmacodynamic approach of unbound plasma propofol during coronary surgery with and without cardiopulmonary bypass (2017)
Silva Filho, Carlos Roberto da; Barbosa, Ricardo Antonio Guimarães; Silva Junior, Carlindo Vieira da; Carmona, Maria José Carvalho; Gomez, David de Souza; Santos, Silvia Regina Cavani Jorge
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Congress of São Paulo. Unidades: FCF, FM
Subjects: CIRURGIA TORÁCICA, FARMACOCINÉTICA, FARMACODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA FILHO, Carlos Roberto da et al. Pharmacokinetic-pharmacodynamic approach of unbound plasma propofol during coronary surgery with and without cardiopulmonary bypass. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 18 nov. 2024. , 2017
APA
Silva Filho, C. R. da, Barbosa, R. A. G., Silva Junior, C. V. da, Carmona, M. J. C., Gomez, D. de S., & Santos, S. R. C. J. (2017). Pharmacokinetic-pharmacodynamic approach of unbound plasma propofol during coronary surgery with and without cardiopulmonary bypass. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Silva Filho CR da, Barbosa RAG, Silva Junior CV da, Carmona MJC, Gomez D de S, Santos SRCJ. Pharmacokinetic-pharmacodynamic approach of unbound plasma propofol during coronary surgery with and without cardiopulmonary bypass. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 80 res. CFSP142.[citado 2024 nov. 18 ]
Vancouver
Silva Filho CR da, Barbosa RAG, Silva Junior CV da, Carmona MJC, Gomez D de S, Santos SRCJ. Pharmacokinetic-pharmacodynamic approach of unbound plasma propofol during coronary surgery with and without cardiopulmonary bypass. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 80 res. CFSP142.[citado 2024 nov. 18 ]
Trabalho de evento-resumo periodico
Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? (2017)
Silva, Vedilaine Aparecida Bueno da; Silva Júnior, João Manoel da; Campos, Edvaldo Vieira de; Silva Junior, Carlindo Vieira da; Gomez, David de Souza; Santos, Silvia Regina Cavani Jorge
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Congress of São Paulo. Unidade: FCF
Subjects: STAPHYLOCOCCUS, FARMACOCINÉTICA, FARMACODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Vedilaine Aparecida Bueno da et al. Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics?. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 18 nov. 2024. , 2017
APA
Silva, V. A. B. da, Silva Júnior, J. M. da, Campos, E. V. de, Silva Junior, C. V. da, Gomez, D. de S., & Santos, S. R. C. J. (2017). Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Silva VAB da, Silva Júnior JM da, Campos EV de, Silva Junior CV da, Gomez D de S, Santos SRCJ. Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 113 res. CFSP209.[citado 2024 nov. 18 ]
Vancouver
Silva VAB da, Silva Júnior JM da, Campos EV de, Silva Junior CV da, Gomez D de S, Santos SRCJ. Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 113 res. CFSP209.[citado 2024 nov. 18 ]

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024